In this context, our results clearly show that a single FH injection at early (6 months) or late (9 months) AD stages improves cognitive functions in APP/PS1 mice by increasing synaptic transmission and decreasing Aβ deposits, complement activation and cytokine release, demonstrating that FH could be a promising target for Alzheimer’s disease treatment (Figure 8). This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.